| Ytd | 26.21% | |
| 1y | 178.56% |
| Open | 12.04 | Prev Close | 12.06 | Low | 11.67 | High | 12.06 | Mkt Cap | 753.23M |
| Vol | 219.26K | Avg Vol | 984.72K | EPS | -1.20 | P/E | -10.05 | Forward P/E | -5.13 |
| Beta | 1.58 | Short Ratio | 19.61 | Inst. Own | 56.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-28 | 50-d Avg | 12.65 | 200-d Avg | 10.40 | 1yr Est | 7.00 |
DSGN News
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatmen
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to ta
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clini
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
Dow falls over 100 points, NASDAQ down 1.20% and S&P 500 down 0.64%. Energy shares surge, tech s
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ata
DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endo
CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clin
Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares de
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investo
U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapir
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) have received an average recomm
CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clin
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) gapped up prior to trading on F
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report)'s stock price traded down 4.5% during mid
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clin
The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter re
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic
On Friday, 469 companies hit new 52-week lows.
On Friday, 497 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.